A Phase II Study of FOLFOX Combined With Nab-Paclitaxel (FOLFOX-A) in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma. Big Ten Cancer Research Consortium: BTCRC-GI15-015
Latest Information Update: 12 Feb 2024
Price :
$35 *
At a glance
- Drugs Paclitaxel (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 13 Oct 2023 Status changed from active, no longer recruiting to completed.
- 18 Jan 2023 Planned End Date changed from 30 Aug 2023 to 1 Feb 2024.
- 18 Jan 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Jun 2023.